These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 18324488

  • 1. Renal impairment and amphotericin B formulations in patients with invasive fungal infections.
    Saliba F, Dupont B.
    Med Mycol; 2008 Mar; 46(2):97-112. PubMed ID: 18324488
    [Abstract] [Full Text] [Related]

  • 2. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ.
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [Abstract] [Full Text] [Related]

  • 3. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M, Letscher-Bru V, Herbrecht R.
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.
    Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ, Viscoli C, Amphotericin B Systematic Review Study Group.
    Clin Ther; 2003 May; 25(5):1295-320. PubMed ID: 12867214
    [Abstract] [Full Text] [Related]

  • 7. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL.
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [Abstract] [Full Text] [Related]

  • 8. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G, Luna M, Lewis RE, Chemaly R, Raad II, Kontoyiannis DP.
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [Abstract] [Full Text] [Related]

  • 9. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
    Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP.
    Pharmacoeconomics; 2004 Sep; 22(5):301-10. PubMed ID: 15061680
    [Abstract] [Full Text] [Related]

  • 10. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
    Kato H, Hagihara M, Yamagishi Y, Shibata Y, Kato Y, Furui T, Watanabe H, Asai N, Koizumi Y, Mikamo H.
    J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
    [Abstract] [Full Text] [Related]

  • 11. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
    Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL.
    Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260
    [Abstract] [Full Text] [Related]

  • 12. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M, Martino R, Gómez L, Martí JM, Estany C, Sierra J.
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.
    Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE.
    Br J Haematol; 1997 Sep; 98(3):711-8. PubMed ID: 9332329
    [Abstract] [Full Text] [Related]

  • 15. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
    Cannon JP, Garey KW, Danziger LH.
    Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of albumin dialysis on pharmacokinetics of amphotericin B colloidal dispersion and amphotericin B lipid complex.
    Weiler S, Vogelsinger H, Joannidis M, Dunzendorfer S, Bellmann R.
    Artif Organs; 2011 Jun; 35(6):667-71. PubMed ID: 21668831
    [Abstract] [Full Text] [Related]

  • 18. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
    Petrikkos GL.
    Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
    [Abstract] [Full Text] [Related]

  • 19. [New lipid formulations of amphotericin B. Review of the literature].
    Andrès E, Tiphine M, Letscher-Bru V, Herbrecht R.
    Rev Med Interne; 2001 Feb; 22(2):141-50. PubMed ID: 11234672
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.
    Sidhu R, Lash DB, Heidari A, Natarajan P, Johnson RH.
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.